[MSB-55] Surgical Treatment of Infective Endocarditis.

IF 0.5 4区 医学 Q4 SURGERY
Özer Kandemir, Murat Koç, Bahadır Gültekin, Ufuk Mungan, Kaan Kaya, İbrahim Duvan, Ferit Çiçekçioğlu
{"title":"[MSB-55] Surgical Treatment of Infective Endocarditis.","authors":"Özer Kandemir, Murat Koç, Bahadır Gültekin, Ufuk Mungan, Kaan Kaya, İbrahim Duvan, Ferit Çiçekçioğlu","doi":"10.5606/tgkdc.dergisi.2024.msb-55","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to offer an analysis of our surgical experience in patients with active infective endocarditis (IE).</p><p><strong>Methods: </strong>The retrospective study included 29 patients who underwent surgery for active IE between December 1, 2022, and August 31, 2024. Patients received valve replacement or repair, debridement of infected tissues, or explantation and replacement of infected prosthetic devices.</p><p><strong>Results: </strong>The operative and early mortality rate was 30% (n=9). Postoperative complications occurred in 24.1% of patients. Advanced age, heart failure, prosthetic valve endocarditis, and <i>Staphylococcus aureus</i> infection were associated with higher mortality rates. Postoperative complications included reexploration of the thoracic cavity, pacemaker implantation, hemodialysis, deep sternal infections, and further valve surgery for three patients.</p><p><strong>Conclusion: </strong>Surgical treatment of IE remains crucial and life-saving, particularly for patients unresponsive to antibiotic therapy or those with complications. Early diagnosis, prompt antibiotic initiation, and timely surgical intervention are essential for optimal outcomes.</p>","PeriodicalId":49413,"journal":{"name":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","volume":"32 4 Suppl 2","pages":"081-81"},"PeriodicalIF":0.5000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045200/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5606/tgkdc.dergisi.2024.msb-55","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to offer an analysis of our surgical experience in patients with active infective endocarditis (IE).

Methods: The retrospective study included 29 patients who underwent surgery for active IE between December 1, 2022, and August 31, 2024. Patients received valve replacement or repair, debridement of infected tissues, or explantation and replacement of infected prosthetic devices.

Results: The operative and early mortality rate was 30% (n=9). Postoperative complications occurred in 24.1% of patients. Advanced age, heart failure, prosthetic valve endocarditis, and Staphylococcus aureus infection were associated with higher mortality rates. Postoperative complications included reexploration of the thoracic cavity, pacemaker implantation, hemodialysis, deep sternal infections, and further valve surgery for three patients.

Conclusion: Surgical treatment of IE remains crucial and life-saving, particularly for patients unresponsive to antibiotic therapy or those with complications. Early diagnosis, prompt antibiotic initiation, and timely surgical intervention are essential for optimal outcomes.

[MSB-55]感染性心内膜炎的外科治疗。
目的:本研究旨在分析我们治疗活动性感染性心内膜炎(IE)患者的手术经验。方法:回顾性研究包括29例在2022年12月1日至2024年8月31日期间接受手术治疗的活动性IE患者。患者接受瓣膜置换术或修复,感染组织清创,或移植并更换感染的假体装置。结果:手术死亡率和早期死亡率为30% (n=9)。术后并发症发生率为24.1%。高龄、心力衰竭、人工瓣膜心内膜炎和金黄色葡萄球菌感染与较高的死亡率相关。术后并发症包括再次探查胸腔、植入起搏器、血液透析、胸骨深部感染和3例进一步的瓣膜手术。结论:手术治疗IE仍然是至关重要和挽救生命的,特别是对抗生素治疗无反应或有并发症的患者。早期诊断,及时使用抗生素和及时的手术干预是获得最佳结果的必要条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
98
审稿时长
3-8 weeks
期刊介绍: The Turkish Journal of Thoracic and Cardiovascular Surgery is an international open access journal which publishes original articles on topics in generality of Cardiac, Thoracic, Arterial, Venous, Lymphatic Disorders and their managements. These encompass all relevant clinical, surgical and experimental studies, editorials, current and collective reviews, technical know-how papers, case reports, interesting images, How to Do It papers, correspondences, and commentaries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信